Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
1 January 1996 | Volume 124 Issue 1 Part 1 | Pages 27-30
Objective: To determine whether herpes simplex virus type 1 (HSV-1) causes Bell palsy.
Design: Prospective study.
Setting: University inpatient service.
Patients: 14 patients with Bell palsy, 9 patients with the Ramsay-Hunt syndrome, and 12 other controls.
Measurements: Viral genomes of HSV-1, varicella-zoster virus, and Epstein-Barr virus were analyzed in clinical samples of facial nerve endoneurial fluid and posterior auricular muscle using polymerase chain reaction (PCR) followed by hybridization with Southern blot analysis.
Results: Herpes simplex virus type 1 genomes were detected in 11 of 14 patients (79%) with Bell palsy but not in patients with the Ramsay-Hunt syndrome or in other controls. The nucleotide sequences of the PCR fragments were identical to those of the HSV-1 genome.
Conclusions: Herpes simplex virus type 1 is the major etiologic agent in Bell palsy.
Many events, such as viral infection [1, 3, 4], ischemia [5], and autoimmune reaction [6], have been proposed as causes of Bell palsy. Viral infection is thought to be the most likely cause [7]. However, it is rare to find a diagnostic fourfold increase in specific viral antibody titer in the acute and convalescent serum specimens of patients with Bell palsy [3, 4, 7]. Postmortem histopathologic studies of the facial nerve suggest viral neuritis [8], but electron microscopic studies have failed to detect specific viral particles in the facial nerve [9]. Because the etiologic agent of Bell palsy is unknown, treatment of this condition is empiric, varying from observation alone to the use of steroids, surgical decompression, and antiviral agents.
We analyzed the viral genomes of herpes simplex virus type 1 (HSV-1), varicella-zoster virus, and Epstein-Barr virus using polymerase chain reaction (PCR) on facial nerve endoneurial fluid specimens and specimens of posterior auricular muscle innervated by the facial nerve.
During a 4-year period, 14 of 170 patients with Bell palsy and 9 of 51 patients with the Ramsay-Hunt syndrome had decompression surgery 12 to 87 days after the onset of facial palsy. None had benefited from medical management. All patients and controls gave informed consent.
Two types of clinical specimens were collected intraoperatively: endoneurial fluid from the facial nerve and tissue from the posterior auricular muscle. A piece of auricular muscle was resected after skin incision, and we obtained endoneurial fluid by absorbing it with a small, sterilized surgical sponge held at the mastoid segment immediately after the epineural sheath was incised. We stored both specimens immediately at 80 °C and continued to store them at that temperature until PCR analysis was done. Control specimens of endoneurial fluid and posterior auricular muscle were collected during decompression surgery from four patients with temporal bone fracture or bacterial infection concomitant with otitis media. Posterior auricular muscle specimens were obtained during tympanoplasty from five patients with chronic otitis media who did not have facial paralysis. As an additional control, a piece of neural tissue was obtained from each of three patients with parotid tumors or facial neuroma whose facial nerves had already been affected (Table 1). BRIEF COMMUNICATION
Bell Palsy and Herpes Simplex Virus: Identification of Viral DNA in Endoneurial Fluid and Muscle
Bell palsy is the most common cause of facial paralysis worldwide; it has an incidence of 20 to 30 per 100 000 persons [1]. Although the second most frequent cause of facial paralysis, the Ramsay-Hunt syndrome, is known to be caused by reactivated varicella-zoster virus [2], the etiologic agent responsible for Bell palsy has not been identified.
Methods
![]()
Top
Methods
Results
Discussion
Author & Article Info
References
Patients and Specimens
|
Polymerase Chain Reaction
To amplify and identify the HSV, varicella-zoster virus, and Epstein-Barr virus genomes, five sets of virus-specific primers and internal oligonucleotide probes were synthesized for PCR and Southern blot analysis. Primer set 1 was prepared for amplification of the HSV-1 genome, which is located on the US6 gene [10]. Primer set 2 was designed to amplify both HSV-1 and HSV-2. A sense primer (5'-CCACCGAGCGGCAGGTGATC-3') and an antisense primer (5'-GCCGACCGCCTGCTCGTGCT-3') are located on the UL44-45 gene [11]. Using primer set 2, we discriminated between HSV-1 (578 base pairs) and HSV-2 (621 base pairs) on the basis of size. Nucleotide sequences of the HSV specific internal probe are 5'-GAGGCGATCGAGTGGGT-3'. Primer sets 3 and 4 were prepared for varicella-zoster virus amplification (genes 29 and 62, respectively) [12], and primer set 5 was prepared for Epstein-Barr virus amplification (latent cycle gene) [13].
The sensitivities of the primer sets were assessed by making serial 10-fold dilutions of each purified DNA sample. The limits of detection for primer sets 1, 2, 3, 4, and 5 were about 10, 100, 10, 100, and 10 femtograms, respectively.
Samples of endoneurial fluid (about 10 µL), posterior auricular muscle (2 mg to 5 mg), and nerve tissue (0.5 mg to 1 mg) were completely digested with proteinase K. Polymerase chain reaction amplification and subsequent hybridization with Southern blot analysis were done as described previously [14]. Rigid precautions against contamination in the sample processing included the use of water controls replacing the DNA samples in all amplifications.
Serum Antibody Titers
We examined serum antibody titers by using the complement fixation test for HSV-1 and varicella-zoster virus and by using fluorescent antibody methods for Epstein-Barr virus 8 to 38 days after the onset of facial paralysis.
Results
|
|---|
|
|
|---|
|
We detected varicella-zoster virus DNA from gene 29 or gene 62 in specimens obtained from patients with the Ramsay-Hunt syndrome only Figure 1, middle; (Table 1). Gene 29 was detected in 8 of the 9 patients (89%), and gene 62 was detected in 6 of the 9 patients (67%). On the other hand, we could not amplify HSV-1, varicella-zoster virus, or Epstein-Barr virus DNA from any specimens obtained from the other controls Figure 1, bottom; (Table 1).
Serum antibody titer to HSV-1 was positive in 12 of 13 patients (92%) with Bell palsy, in 4 of 9 patients (44%) with the Ramsay-Hunt syndrome, and in 5 of 9 controls (56%) (Table 1). The prevalence of HSV-1 antibody in patients with Bell palsy was significantly higher than that in controls (P < 0.05, Fisher exact test). However, antibody titers to HSV-1 in patients with Bell palsy were not significantly higher than those of controls, as previously reported [3, 4].
Discussion
|
|---|
|
|
|---|
Triggers known to be associated with Bell palsy are also known to reactivate HSV. Preceding stress, such as upper respiratory tract infection, fever, dental extraction, menstruation, or exposure to cold might reactivate latent HSV-1 in the geniculate ganglion. After the virus reactivates, it destroys ganglion cells and spreads into the endoneurial fluid. The virus also infects Schwann cells, leading to demyelinization and inflammation of the facial nerve [19]. This inflammatory response has been shown by gadolinium-enhanced magnetic resonance imaging in patients with Bell palsy and in patients with the Ramsay-Hunt syndrome [20].
Given the known neuropathogenicity of HSV-1 and the presence of HSV-1 DNA in the lesional site of the facial nerve specific to patients with Bell palsy, we conclude that HSV-1 infection in the facial nerve is directly related to the pathogenesis of Bell palsy just as the varicella-zoster virus is directly related to the pathogenesis of the Ramsay-Hunt syndrome. There are two possible explanations for our failure to detect HSV-1 in three of the patients with Bell palsy [patients 9, 12, and 13]: 1) the limited sensitivity of PCR analysis to detect small amounts of viral DNA and 2) the presence of an etiologic agent other than HSV-1. More data are required to determine the percentage of patients with Bell palsy in whom HSV-1 is the etiologic agent of Bell palsy, but our findings suggest that HSV-1 infection is the major cause of Bell palsy and that treatment with appropriate antiviral agents might benefit most patients with this condition.
Drs. Mizobuchi, Nakashiro, and Doi: Department of Neuropsychiatry, Ehime University School of Medicine, Shigenobu-cho, Onsen-gun, Ehime 791-02, Japan.
Author and Article Information
|
|---|
|
|
|---|
References
|
|---|
|
|
|---|
1. Hadar T, Tovi F, Sidi J, Sarov B, Sarov I. Specific IgG and IgA antibodies to herpes simplex virus and varicella zoster virus in acute peripheral facial palsy patients. J Med Virol. 1983; 12:237-45.
2. Aitken RS, Brain RT. Facial palsy and infection with zoster virus. Lancet. 1933; 1:19-22.
3. McCormick DP. Herpes-simplex virus as a cause of Bell's palsy. Lancet. 1972; 1:937-9.
4. Adour KK, Bell DN, Hilsinger RL Jr. Herpes simplex virus in idiopathic facial paralysis (Bell palsy). JAMA. 1975; 233:527-30.
5. Devriese PP. Compression and ischaemia of the facial nerve. Acta Otolaryngol (Stockh). 1974; 77:108-18.
6. Abramsky O, Webb C, Teitelbaum D, Arnon R. Cellular immune response to peripheral nerve basic protein in idiopathic facial paralysis (Bell's palsy). J Neurol Sci. 1975; 26:13-20.
7. Spruance SL. Bell palsy and herpes simplex virus [Editorial]. Ann Intern Med. 1994; 120:1045-6.
8. Liston SL, Kleid MS. Histopathology of Bell's palsy. Laryngoscope. 1989; 99:23-6.
9. Palva T, Hortling L, Ylikoski J, Collan Y. Viral culture and electron microscopy of ganglion cells in Meniere's disease and Bell's palsy. Acta Otolaryngol (Stockh). 1978; 86:269-75.
10. Aurelius E, Johansson B, Skoldenberg B, Staland A, Forsgren M. Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid. Lancet. 1991; 337:189-92.
11. Dowbenko DJ, Lasky LA. Extensive homology between the herpes simplex virus type 2 glycoprotein F gene and the herpes simplex virus type 1 glycoprotein C gene. J Virol. 1984; 52:154-63.
12. Gilden DH, Dueland AN, Devlin ME, Mahalingam R, Cohrs R. Varicellazoster virus reactivation without rash. J Infect Dis. 1992; 166(Suppl 1):S30-4.
13. Cinque P, Brytting M, Vago L, Castagna A, Parravicini C, Zanchetta N, et al. Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet. 1993; 342:398-401.
14. Mizobuchi M, Frohman MA, Downs TR, Frohman LA. Tissue- specific transcription initiation and effects of growth hormone (GH) deficiency on the regulation of mouse and rat GH-releasing hormone gene in hypothalamus and placenta. Mol Endocrinol. 1991; 5:476-84.
15. Furuta Y, Takasu T, Fukuda S, Sato-Matsumura KC, Inuyama Y, Hondo R, et al. Detection of varicella-zoster virus DNA in human geniculate ganglia by polymerase chain reaction. J Infect Dis. 1992; 166:1157-9.
16. Takasu T, Furuta Y, Sato KC, Fukuda S, Inuyama Y, Nagashima K. Detection of latent herpes simplex virus DNA and RNA in human geniculate ganglion by the polymerase chain reaction. Acta Otolaryngol (Stockh). 1992; 122:1004-11.
17. Burgess RC, Michaels L, Bale JF Jr, Smith RJ. Polymerase chain reaction amplification of herpes simplex viral DNA from the geniculate ganglion of a patient with Bell's palsy. Ann Otol Rhinol Laryngol. 1994; 103:775-9.
18. Carton CA. Effect of previous sensory loss on the appearance of herpes simplex. J Neurosurg. 1953; 10:463-8.
19. Townsend JJ, Collins PK. Peripheral nervous system demyelination with herpes simplex virus. J Neuropathol Exp Neurol. 1986; 45:419-25.
20. Sartoretti-Schefer S, Wichmann W, Valavanis A. Idiopathic, herpetic, and HIV-associated facial nerve palsies: abnormal MR enhancement patterns. AJNR Am J Neuroradiol. 1994; 15:479-85.
This article has been cited by other articles:
![]() |
Update on managing bell's palsy DTB, July 1, 2008; 46(7): 53 - 54. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Gilden and K. L. Tyler Bell's Palsy -- Is Glucocorticoid Treatment Enough? N. Engl. J. Med., October 18, 2007; 357(16): 1653 - 1655. [Full Text] [PDF] |
||||
![]() |
D. L Alberton and P. J Zed Bell's Palsy: A Review of Treatment Using Antiviral Agents Ann. Pharmacother., October 1, 2006; 40(10): 1838 - 1842. [Abstract] [Full Text] [PDF] |
||||
![]() |
Managing Bell's palsy DTB, July 1, 2006; 44(7): 49 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
L J Vanopdenbosch, K Verhoeven, and J W Casselman Bell's palsy with ipsilateral numbness J. Neurol. Neurosurg. Psychiatry, July 1, 2005; 76(7): 1017 - 1018. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Stuart, S. A. Strite, J. A. Magaldi, H. R. Djalilian, and D. H. Gilden Bell's Palsy N. Engl. J. Med., January 27, 2005; 352(4): 416 - 418. [Full Text] [PDF] |
||||
![]() |
D. H. Gilden Bell's Palsy N. Engl. J. Med., September 23, 2004; 351(13): 1323 - 1331. [Full Text] [PDF] |
||||
![]() |
N J. Holland and G. M Weiner Recent developments in Bell's palsy BMJ, September 4, 2004; 329(7465): 553 - 557. [Full Text] [PDF] |
||||
![]() |
M. Strupp, V. C. Zingler, V. Arbusow, D. Niklas, K. P. Maag, M. Dieterich, S. Bense, D. Theil, K. Jahn, and T. Brandt Methylprednisolone, Valacyclovir, or the Combination for Vestibular Neuritis N. Engl. J. Med., July 22, 2004; 351(4): 354 - 361. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mutsch, W. Zhou, P. Rhodes, M. Bopp, R. T. Chen, T. Linder, C. Spyr, and R. Steffen Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland N. Engl. J. Med., February 26, 2004; 350(9): 896 - 903. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||